Skip to main content
. 2012 Sep;5(5):275–283. doi: 10.1177/1756283X11417037

Table 1.

Summary of baseline characteristics of all patients included as part of the study population.

Characteristic n (%) unless otherwise indicated
Age 56.40 (9.43)*
Male sex 43 (78.18)
Race
 African American 21 (38.18)
 White 26 (47.27)
 Other$ 8 (14.55)
Cause of cirrhosis
 Hepatitis C 16 (29.09)
 Alcohol 14 (25.45)
 Hepatitis C and alcohol 10 (18.18)
 Hepatitis B 3 (5.45)
 Nonalcoholic steatohepatitis 3 (5.45)
 Cryptogenic cirrhosis 3 (5.45)
 Other# 6 (10.90)
MELD score 23.80 (8.43)*
Serum creatinine 1.70 (1.20, 2.60)
Serum bilirubin 5.40 (2.10, 11.60)
Serum INR 1.60 (1.40, 2.10)
Serum sodium 133.09 (7.43)*
Immunocompromised status 6 (10.91)
Variceal hemorrhage 8 (14.55)
On antibiotics at time of diagnosis 5 (9.09)
Gram-stain positive 6 (13.95)§
Initial peritoneal fluid PMN cell count 773.10 (517.50, 2188.80)
Repeat peritoneal fluid PMN cell count 127.60 (56.60, 607.60)
Peritoneal fluid culture positive** 22 (40.00)
Gram positive 8 (14.54)
Gram negative 11 (20.00)

INR, international normalized ratio; MELD, model for end-stage liver disease; PMN, polymorphonyclear.

*

Mean (SD).

$

Other races: Hispanic (6), Middle Eastern (1), Eygptian (1).

#

Other causes of ascites: cirrhosis from alpha-1-antitrypsin deficiency (2), autoimmune hepatitis (2), giant-cell hepatitis (1), biliary obstruction (1).

Median (Q1, Q3).

Antibiotic regimens: ciprofloxacin weekly for prophylaxis of spontaneous bacterial peritonitis (SBP) (1), ciprofloxacin weekly for SBP prophylaxis and metronidazole for extraperitoneal infection (1), trimethoprim and sulfamethoxazole prophylaxis for patient with HIV (1). Other antibiotic regimens for extraperitoneal infections included dapsone/trimethoprim and sulfamethoxazole/ampicillin (1), vancomycin/cefepime (1).

§

Gram stain not performed on 12 (21.81) patients.

**

Peritoneal fluid culture was negative in 31 (56.36%) patients and not performed on 2 (3.63%) patients. Fluid culture was multi-organismal in 3 (5.45%) patients.